Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3

Alimentary Pharmacology and Therapeutics

Volumn 47, Issue 2, 2018, Pages 259-267

  Younossi, Z M ^a   Stepanova, M ^a   Jacobson, I M ^a   Asselah, T ^a   Gane, E J ^a   Lawitz, E ^a   Foster, G R ^b   Roberts, S K ^a   Thompson, A J ^a   Willems, B E ^a   Welzel, T M ^a   Pearlman, B ^a   Younossi, I ^a   Racila, A ^a   Henry, L ^a  

^a Falls Church ^*  (United States)

^b London   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SOFOSBUVIR PLUS VELPATASVIR; VOXILAPREVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; MACROCYCLIC COMPOUND; SOFOSBUVIR; SULFONAMIDE; VELPATASVIR;

ADULT; AGE; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; CHRONIC HEPATITIS C; DEPRESSION; DRUG EFFICACY; FEMALE; FOLLOW UP; GENDER; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; SHORT FORM 36; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CARBAMATES; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT REPORTED OUTCOME MEASURES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELF REPORT; SOFOSBUVIR; SULFONAMIDES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85035201864     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14423     Document Type: Article

References (46)

1. Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153:113-122.
2. Feld JJ, Jacobson IM, Hézode C, et al. For the ASTRAL-1 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015;373:2599-2607.
3. Afdhal N, Zeuzem S, Kwo P, et al. ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-1898.
4. Zeuzem S, Dusheiko GM, Salupere R, et al. VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993-2001.
5. Kowdley KV, Gordon SC, Reddy KR, et al. ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888.
6. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with hcv genotype 1b infection. Gastroenterology. 2014;147:359-365.
7. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604-1614.
8. Nelson DR, Cooper JN, Lalezari JP, et al. ALLY-3 study team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127-1135.
9. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756-1765.
10. Jacobson IM, Gordon SC, Kowdley KV, et al., POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-1877.
11. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973-1982.
12. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
13. Afdhal N, Reddy KR, Nelson DR, et al. ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-1493.
14. Foster GR, Afdhal N, Roberts SK, et al., ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015;373:2608-2617.
15. Curry MP, O'Leary JG, Bzowej N, et al. ASTRAL-4 Investigators. sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618-2628.
16. Bourlière M, Gordon SC, Flamm SL, et al. POLARIS-1 and POLARIS-4 investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134-2146.
17. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63:337-345.
18. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients co-infected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis. 2015;212:367-377.
19. Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014;59:2161-2169.
20. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol. 2014;60:741-747.
21. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12:1349-1359.e13.
22. Gerber L, Estep M, Stepanova M, Escheik C, Weinstein A, Younossi ZM. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2016;14:156-164.e3.
23. Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourlière M. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016;36:42-826.
24. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015;61:1798-1808.
25. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol. 2014;61:228-234.
26. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther. 2015;42:286-295.
27. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C–the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497-520.
28. Younossi Z, Henry L. The impact of the new antiviral regimens on patient-reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis. 2014;46(Suppl 5):S186-S196.
29. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/Velpatasvir Improves Patient-Reported Outcomes in HCV Patients: results from ASTRAL-1 Placebo-Controlled Trial. J Hepatol. 2016;65:33-39.
30. Younossi ZM, Stepanova M, Sulkowski M, et al. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study. Liver Int. 2017; https://doi.org/10.1111/liv.13462 [Epub ahead of print].
31. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol. 2017;15:421-430.e6.
32. Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1:122-132.
33. Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from astral-2 and -3 clinical trials. Clin Infect Dis. 2016;63:1042-1048.
34. Younossi ZM1, Stepanova M, Balistreri W, et al. Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir. J Pediatr Gastroenterol Nutr. 2017. https://doi.org/10.1097/MPG.0000000000001754 [Epub ahead of print].
35. Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. an in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol. 2016;111:808-816. https://doi.org/10.1038/ajg.2016.99 [Epub ahead of print].
36. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.11.
37. Webster K, Odom L, Peterman A, et al. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res. 1999;8:604.
38. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295-300.
39. Younossi ZM, Stepanova M, Henry L. Performance and validation of chronic liver disease questionnaire-hepatitis C version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C. Value Health. 2016;19:544-551.
40. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353-365.
41. Kharroubi SA, Brazier JE, Roberts J, O'Hagan A. Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ. 2007;26:597-612.
42. Voaklander R, Jacobson IM. Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C. Expert Rev Gastroenterol Hepatol. 2017;11:789-795.
43. Morgan TR, Ghany MG, Kim HY, et al. HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833-844.
44. Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:1450-1455.
45. Anderson RT, Baran RW, Erickson P, Revicki DA, Dietz B, Gooch K. Psychometric evaluation of the hepatitis C virus patient-reported outcomes (HCV-PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Qual Life Res. 2014;23:877-886.
46. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41:790-800.